Skip to main content
SpringerLink
Log in

The Global Economic Impact of Neurodegenerative Diseases: Opportunities and Challenges

  • Chapter
  • First Online:
Bioeconomy for Sustainable Development

Abstract

The main challenge in today’s world to the healthcare system is the elevated occurrence of the neurodegenerative disorders. Progress in the field of bioinformatics and biomedical research has allowed us to understand the pathobiology of the neurodegenerative disorders in a detailed manner. The threat of these diseases increases with aging, and Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and Huntington’s disease are the major ones affecting the public health and posing the higher economic burden. The research centers, pharmaceutical companies, and academic institutions are conducting research work in collaborations these days to enhance the development of new therapeutic strategies and develop novel drugs in a sustainable way. This can help in the development of safer therapies with reduced risk and can help in developing the authentic and evident biomarkers so that the disease can be diagnosed at early stages and treated accordingly. The advancement can therefore help in improving the quality of life of patients suffering from these debilitating neurodegenerative disorders and can also help in providing the job opportunities to the students interested in drug development program.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • Agnati LF, Zoli M, Biagini G, Fuxe K (1992) Neuronal plasticity and ageing processes in the frame of the ‘red queen theory’. Acta Physiol Scand 145(4):301–309

    Article  CAS  Google Scholar 

  • Aisen PS, Cummings J, Jack CR, Morris JC, Sperling R, Frölich L, Jones RW, Dowsett SA, Matthews BR, Raskin J, Scheltens P (2017) On the path to 2025: understanding the Alzheimer’s disease continuum. Alzheimers Res Ther 9(1):60

    Article  CAS  Google Scholar 

  • ALS Association (2015) Available on URL: http://www.alsa.org/news/media/press-releases/new-research-grants-2015.html. Accessed 06/03/2019

  • Alzheimer’s Association (2018) Alzheimer’s disease facts and figures. Alzheimers Dement 14(3):367–429

    Article  Google Scholar 

  • Bano D, Zanetti F, Mende Y, Nicotera P (2011) Neurodegenerative processes in Huntington’s disease. Cell Death Dis 2(11):e228

    Article  CAS  Google Scholar 

  • Boillée S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, Kollias G, Cleveland DW (2006) Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312(5778):1389–1392

    Article  CAS  Google Scholar 

  • Borras-Blasco J, Plaza-Macías I, Navarro-Ruiz A, Peris-Marti J, Anton-Cano A (1998) Riluzole as a treatment for amyotrophic lateral sclerosis. Rev Neurol (160):1021–1027

    Google Scholar 

  • Brodaty H, Heffernan M, Kochan NA, Draper B, Trollor JN, Reppermund S, Slavin MJ, Sachdev PS (2013) Mild cognitive impairment in a community sample: the Sydney memory and ageing study. Alzheimer’s Dement. 1 9(3):310–317

    Article  Google Scholar 

  • Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM (2007) Forecasting the global burden of Alzheimer’s disease. Alzheimer’s Dement. 1 3(3):186–191

    Article  Google Scholar 

  • Business Wire (2018) Available on URL: https://www.businesswire.com/news/home/20180305005266/en/Parkinson%E2%80%99s-Institute-Clinical-Center-Collaborates-Denali-Therapeutics. Accessed 04/03/2019

  • Carter AJ, Donner A, Lee WH, Bountra C (2017) Establishing a reliable framework for harnessing the creative power of the scientific crowd. PLoS Biol 15(2):e2001387

    Article  CAS  Google Scholar 

  • Cummings JL, Morstorf T, Zhong K (2014) Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther 6(4):37

    Article  Google Scholar 

  • Cummings J, Lee G, Mortsdorf T, Ritter A, Zhong K (2017) Alzheimer’s disease drug development pipeline: 2017. Alzheimer’s Dement: Transl Res Clin Interv 3(3):367–384

    Google Scholar 

  • Cummings J, Reiber C, Kumar P (2018) The price of progress: funding and financing Alzheimer’s disease drug development. Alzheimer’s Dement: Trans Res Clin Interv 4:330–343

    Google Scholar 

  • Deb A, Thornton JD, Sambamoorthi U, Innes K (2017) Direct and indirect cost of managing alzheimer’s disease and related dementias in the United States. Expert Rev Pharmacoecon Outcomes Res 17(2):189–202

    Article  Google Scholar 

  • Deflorio C, Onesti E, Lauro C, Tartaglia G, Giovannelli A, Limatola C, Inghilleri M, Grassi F (2014) Partial block by riluzole of muscle sodium channels in myotubes from amyotrophic lateral sclerosis patients. Neurol Res Int 2014:946073

    Article  Google Scholar 

  • Delamarre A, Meissner WG (2017) Epidemiology, environmental risk factors and genetics of Parkinson’s disease. La Presse Med 46(2):175–181

    Article  Google Scholar 

  • Deng Y, Xu Z, Xu B, Tian Y, Xin X, Deng X, Gao J (2009) The protective effect of riluzole on manganese caused disruption of glutamate–glutamine cycle in rats. Brain Res 1289:106–117

    Article  CAS  Google Scholar 

  • DiMasi JA, Grabowski HG, Hansen RW (2016) Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ 1(47):20–33

    Article  Google Scholar 

  • Domingo A, Klein C (2018) Genetics of Parkinson disease. Handb Clin Neurol 147:211–227 Elsevier

    Google Scholar 

  • Dragojlovic N, Lynd LD (2014) Crowdfunding drug development: the state of play in oncology and rare diseases. Drug Discov Today 19(11):1775–1780

    Article  Google Scholar 

  • Durães F, Pinto M, Sousa E (2018) Old drugs as new treatments for neurodegenerative diseases. Pharmaceuticals 11(2):44

    Article  CAS  Google Scholar 

  • Fleming JJ (2015) The decline of venture capital investment in early-stage life sciences poses a challenge to continued innovation. Health Aff 34(2):271–276

    Article  Google Scholar 

  • Gammon K (2014) Neurodegenerative disease: brain windfall. Nature 515(7526):299–300

    Article  Google Scholar 

  • Gitler AD, Dhillon P, Shorter J (2017) Neurodegenerative disease: models, mechanisms, and a new hope. Dis Model Mech 10:499–502

    Article  CAS  Google Scholar 

  • Gordon PH (2013) Amyotrophic lateral sclerosis: an update for 2013 clinical features, pathophysiology, management and therapeutic trials. Aging Dis 4(5):295

    Article  Google Scholar 

  • Gordon PH, Cheng B, Katz IB, Pinto M, Hays AP, Mitsumoto H, Rowland LP (2006) The natural history of primary lateral sclerosis. Neurology 66(5):647–653

    Article  CAS  Google Scholar 

  • Greenhalgh T, Ovseiko PV, Fahy N, Shaw S, Kerr P, Rushforth AD, Channon KM, Kiparoglou V (2017) Maximising value from a United Kingdom biomedical research Centre: study protocol. Health Res Policy Syst 15(1):70

    Article  Google Scholar 

  • Harris BT (2014) Amyotrophic lateral sclerosis. In: Pathobiology of human disease: a dynamic encyclopedia of disease mechanisms. Elsevier, Waltham

    Chapter  Google Scholar 

  • Heinrich M (2010) Galanthamine from Galanthus and other Amaryllidaceae–chemistry and biology based on traditional use. Alkaloids Chem Biol 68:157–165. Academic Press

    Article  CAS  Google Scholar 

  • Hurtado-Puerto AM, Russo C, Fregni F (2018) Alzheimer’s disease. In: Neuromethods. Humana Press, New York

    Google Scholar 

  • Hwang JY, Aromolaran KA, Zukin RS (2017) The emerging field of epigenetics in neurodegeneration and neuroprotection. Nat Rev Neurosci 18(6):347

    Article  CAS  Google Scholar 

  • Keswani C, Bisen K, Singh SP, Singh HB (2017) Traditional knowledge and medicinal plants of India in intellectual property landscape. Med Plants 9(1):1–11

    Google Scholar 

  • Kumar A, Singh A (2015) A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacol Rep 67(2):195–203

    Article  CAS  Google Scholar 

  • Lawrence S (2017) Biotech's wellspring—a survey of the health of the private sector in 2016. Nat Biotechnol 35(5):413

    Article  CAS  Google Scholar 

  • Lin JY, Xie CL, Zhang SF, Yuan W, Liu ZG (2017) Current experimental studies of gene therapy in Parkinson’s disease. Front Aging Neurosci 9:126

    Article  CAS  Google Scholar 

  • Lo AW, Ho C, Cummings J, Kosik KS (2014) Parallel discovery of Alzheimer’s therapeutics. Sci Transl Med 6(241):241cm5

    Article  Google Scholar 

  • Logroscino G, Traynor BJ, Hardiman O, Couratier P, Mitchell JD, Swingler RJ, Beghi E (2008) Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. J Neurol Neurosurg Psychiatry 79(1):6–11

    Article  CAS  Google Scholar 

  • Lu H, Le WD, Xie YY, Wang XP (2016) Current therapy of drugs in amyotrophic lateral sclerosis. Curr Neuropharmacol 14(4):314–321

    Article  CAS  Google Scholar 

  • MacDonald ME, Ambrose CM, Duyao MP, Myers RH, Lin C, Srinidhi L, Barnes G, Taylor SA, James M, Groot N, MacFarlane H (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72(6):971–983

    Article  Google Scholar 

  • Martorell P, Hurd MD, Delavande A, Mullen KJ, Langa KM (2013) Monetary costs of dementia in the United States. N Engl J Med 368(14):1326–1334

    Article  CAS  Google Scholar 

  • Matyus P, Dunkel P, Chai CL, Sperlagh B, Huleatt PB (2012) Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer’s, Parkinson’s and Huntington’s diseases, and amyotrophic lateral sclerosis. Expert Opin Investig Drugs 21(9):1267–1308

    Article  CAS  Google Scholar 

  • McColgan P, Tabrizi SJ (2018) Huntington’s disease: a clinical review. Eur J Neurol 25(1):24–34

    Article  CAS  Google Scholar 

  • Mucke HA (2015) The case of galantamine: repurposing and late blooming of a cholinergic drug. Future Sci OA 1(4):FSO73

    Article  CAS  Google Scholar 

  • Mulder DW, Kurland LT, Offord KP, Beard CM (1986) Familial adult motor neuron disease: amyotrophic lateral sclerosis. Neurology 36(4):511–517

    Article  CAS  Google Scholar 

  • Muller S, Weigelt J (2010) Open-access public-private partnerships to enable drug discovery – new approaches. IDrugs: Invest Drugs J 13(3):175–180

    Google Scholar 

  • Murphy DG, Goldman M, Loth E, Spooren W (2014) Public-private partnership: a new engine for translational research in neurosciences. Neuron 84(3):533–536

    Article  CAS  Google Scholar 

  • Neymotin A, Petri S, Calingasan NY, Wille E, Schafer P, Stewart C, Hensley K, Beal MF, Kiaei M (2009) Lenalidomide (Revlimid®) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis. Exp Neurol 220(1):191–197

    Article  CAS  Google Scholar 

  • Nguyen HHP, Weydt P (2018) Huntington disease. Med Genet 30(2):246–251

    Google Scholar 

  • Pandya RS, Zhu H, Li W, Bowser R, Friedlander RM, Wang X (2013) Therapeutic neuroprotective agents for amyotrophic lateral sclerosis. Cell Mol Life Sci 70(24):4729–4745

    Article  CAS  Google Scholar 

  • Parayath NN, Pawar G, Avachat C, Miyake MM, Bleier B, Amiji MM (2017) Neurodegenerative disease. In: Nanomedicine for inflammatory diseases. CRC Press, Boca Raton/London, pp 289–318

    Chapter  Google Scholar 

  • Parkinson’s Institute and Clinical Center (2017) Available on URL: http://www.thepi.org/clientuploads/directory/News/PI_CIRM_PR%201_20_2017.pdf. Accessed 05/03/2019

  • Parkinson’s Institute and Clinical Center (2018) Available on URL: http://www.thepi.org/news/2018/02/05/news-articles/exciting-partnership-to-advance-precision-medicine-for-lrrk2/. Accessed 05/03/2019

  • Payami H (2017) The emerging science of precision medicine and pharmacogenomics for Parkinson’s disease. Mov Disord 32(8):1139–1146

    Article  Google Scholar 

  • Perry JJ, Pratt AJ, Getzoff ED (2012) Amyotrophic lateral sclerosis: update and new developments. Degenerative Neurol Neuromuscul Dis 2012(2):1

    Google Scholar 

  • Portilla L, L Rohrbaugh M (2014) Leveraging public private partnerships to innovate under challenging budget times. Curr Top Med Chem 14(3):326–329

    Article  CAS  Google Scholar 

  • Prince M, Comas-Herrera A, Knapp M, et al (2016) World Alzheimer report 2016. In: https://www.alz.co.uk

  • Ramsey BW, Nepom GT, Lonial S (2017) Academic, foundation, and industry collaboration in finding new therapies. N Engl J Med 376(18):1762–1769

    Article  CAS  Google Scholar 

  • Reiman EM, Langbaum J, Fleisher AS, Caselli RJ, Chen K, Ayutyanont N, Quiroz YT, Kosik KS, Lopera F, Tariot PN (2011) Alzheimer’s prevention initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 26(s3):321–329

    Article  Google Scholar 

  • Roberts R, Knopman DS (2013) Classification and epidemiology of MCI. Clin Geriatr Med 29(4):753–772

    Article  Google Scholar 

  • Rowland LP (2001) How amyotrophic lateral sclerosis got its name: the clinical-pathologic genius of Jean-Martin Charcot. Arch Neurol 58(3):512–515

    Article  CAS  Google Scholar 

  • Schumacher-Schuh AF, Rieder CR, Hutz MH (2014) Parkinson’s disease pharmacogenomics: new findings and perspectives. Pharmacogenomics 15(9):1253–1271

    Article  CAS  Google Scholar 

  • Scott TJ, O’connor AC, Link AN, Beaulieu TJ (2014) Economic analysis of opportunities to accelerate Alzheimer’s disease research and development. Ann N Y Acad Sci 1313(1):17–34

    Article  Google Scholar 

  • Sidders B, Brockel C, Gutteridge A, Harland L, Jansen PG, McEwen R, Michalovich D, Seidel H, Weiss B, Williams-Jones B, Woodwark M (2014) Precompetitive activity to address the biological data needs of drug discovery. Nat Rev Drug Discov 13(2):83

    Article  CAS  Google Scholar 

  • Singh HB, Jha A, Keswani C (eds) (2016a) Intellectual property issues in biotechnology. CABI, Wallingford. 304 pages, ISBN-13: 9781780646534

    Google Scholar 

  • Singh HB, Jha A, Keswani C (2016b) Biotechnology in agriculture, medicine and industry: an overview. In: Singh HB, Jha A, Keswani C (eds) Intellectual property issues in biotechnology. CABI, Wallingford, pp 1–4

    Chapter  Google Scholar 

  • The Michael J. Fox Foundation for Parkinson’s disease (2019) Available from URL: https://www.michaeljfox.org/foundation/news-detail.php?what-we-fund-24-million-in-new-grants-for-parkinson-research. Accessed 06/03/2019

  • von Campenhausen S, Winter Y, e Silva AR, Sampaio C, Ruzicka E, Barone P, Poewe W, Guekht A, Mateus C, Pfeiffer KP, Berger K (2011) Costs of illness and care in Parkinson’s disease: an evaluation in six countries. Eur Neuropsychopharmacol 21(2):180–191

    Article  CAS  Google Scholar 

  • Vradenburg G (2015) A pivotal moment in Alzheimer’s disease and dementia: how global unity of purpose and action can beat the disease by 2025. Expert Rev Neurother 15(1):73–82

    Article  CAS  Google Scholar 

  • Wang J, Gu BJ, Masters CL, Wang YJ (2017) A systemic view of Alzheimer disease—insights from amyloid-β metabolism beyond the brain. Nat Rev Neurol 13(10):612

    Article  CAS  Google Scholar 

  • Widdus R (2005) Public-private partnerships: an overview. Trans R Soc Trop Med Hyg 99(Supplement_1):S1–S8

    Article  Google Scholar 

  • Yacoubian TA (2017) Drug discovery approaches for the treatment of neurodegenerative disorders. Academic Press/Elsevier, Amsterdam

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi, India

    Walia Zahra, Sachchida Nand Rai, Hareram Birla, Saumitra Sen Singh, Hagera Dilnashin, Aaina Singh Rathore & Surya Pratap Singh

Authors
  1. Walia Zahra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sachchida Nand Rai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hareram Birla
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Saumitra Sen Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hagera Dilnashin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Aaina Singh Rathore
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Surya Pratap Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi, Uttar Pradesh, India

    Chetan Keswani

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Zahra, W. et al. (2020). The Global Economic Impact of Neurodegenerative Diseases: Opportunities and Challenges. In: Keswani, C. (eds) Bioeconomy for Sustainable Development. Springer, Singapore. https://doi.org/10.1007/978-981-13-9431-7_17

Download citation

Publish with us

Policies and ethics

Search

Navigation